During the past eleven years, our work has focused on HIV infection and cancer metastasis as biological targets. While these may seem like two very different diseases, our studies indicate that both can be addressed using similar chemical strategies. Our research is rooted in three core areas including 1) the development of small molecule inhibitors of critical pathogenic pathways, 2) synthesis of chemically defined macromolecules as vaccine candidates and, 3) the synthesis of immunogenic glycolipids to enhance the effects of chemotherapeutics.


a. Gervay-Hague J, Hadd M., inventors. The Arizona Disease Control Research Commission (Phoenix, AZ), assignee. Disulfone Reagents and Methods of Preparing and Using Same. US 6,812,365. 2004 November 02.

b. Gervay-Hague J, Ying L., inventors. Regents of The University of California, assignee. Labeled Substrate Conjugates for Identifying Enzyme Inhibitors. US 7,527,934. 2009 May 05.

c. Gervay-Hague J, Du W, Kulkarni S, Schombs M., inventors. Regents of The University of California, assignee. One-Pot Synthesis of Alpha/Beta-O- Glycolipids. US 8,624,006. 2014 January 07.

d. Gervay-Hague J, DeNardo S, Du W, Natarajan A., inventors. The Regents of the University of California (Oakland, CA), assignee. Construction of a multivalent scFv through alkyne-azide 1,3- dipolar cycloaddition. US 8,946,391. 2015 February 03.

e. Gervay-Hague J, Schombs M inventors. The Regents of the University of California (Oakland, CA), assignee. Regioselective Silyl Exchange of Per-Silylated Oligosaccharides. US 2016/0176909 A1.